Aggregation of specific proteins are histopathological hallmarks of several
neurodegenerative diseases, such as, Amyloid β (Aβ) plaques and tau neurofibrillary …

Alzheimer Disease (AD) is a neurodegenerative disease characterized by two
neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular …

Amyloid diseases are global epidemics with profound health, social and economic
implications and yet remain without a cure. This dire situation calls for research into the …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the
comorbidity of these brain disorders in aging individuals represents a significant challenge …

Alzheimer's disease (AD) is pathologically defined by the presence of fibrillar amyloid β (Aβ)
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …

Background Synapse damage and loss are fundamental to the pathophysiology of
Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to …

Despite the accumulating evidence linking the development of Alzheimer's disease (AD) to
the aggregation of Aβ peptides and the emergence of Aβ oligomers, the FDA has approved …

Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary human and financial burdens. Studies of …